Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
September 12, 2024 06:57 ET | Aclarion, Inc.
Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard of care addressing...
image2.png
Bedford Metals Provides Corporate Update on Uranium Exploration Progress
September 06, 2024 01:00 ET | Bedford Metals Corp.
Bedford Metals provides corporate update about their uranium exploration efforts in the Athabasca Basin.
66299519da846f373cead802_1.png
Blackwell 3D Provides Corporate Update, Eyes Asian Market
September 03, 2024 06:00 ET | Blackwell 3D Construction Corp.
DUBAI, UAE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Blackwell 3D Construction Corp. (OTC: BDCC) ("Blackwell 3D” or the "Company"), an innovative 3D house printing technology company focused on advancing...
NurExone Logo Rebrand-large.png
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 28, 2024 08:34 ET | NurExone Biologic Inc
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
logo.png
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 16:05 ET | GT Biopharma, Inc.
GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H...
Logo.png
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 08:05 ET | GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
Arbutus Biopharma Logo
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024 07:30 ET | Arbutus Biopharma Corporation
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I...
ARIDIS_LOGO.png
Aridis Provides Corporate Update
June 24, 2024 17:58 ET | Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
LOGO_Kintavar.png
Mise à jour corporative de Kintavar
May 29, 2024 07:43 ET | Kintavar Exploration inc.
MONTRÉAL, 29 mai 2024 (GLOBE NEWSWIRE) -- Kintavar Exploration Inc. (la « Société » ou « Kintavar ») (TSX-V : KTR), est heureuse de fournir une mise à jour corporative détaillant les objectifs...
LOGO_Kintavar.png
Kintavar Corporate Update
May 29, 2024 07:43 ET | Kintavar Explorations Inc.
MONTREAL, May 29, 2024 (GLOBE NEWSWIRE) -- Kintavar Exploration Inc. (the “Corporation” or “Kintavar”) (TSX-V: KTR), is pleased to provide a corporate update detailing the Corporations objectives...